Morris B. Goldman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Morris B. Goldman has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Rajiv Tandon
Department of Psychiatry, University of Florida, Gainesville, FL
3 shared publications Wanlop Atsariyasing
3 shared publicationsAnthony Archer
2 shared publicationsJennifer Kezman
2 shared publications- Lei Wang
The Ohio State University
2 shared publications - Philip G. Janicak
Rush University Medical Center
2 shared publications
Latest Publications
- 1 September 2020
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 34 (5) , 101469
Primary polydipsia: Update
- 1 September 2020
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 34 (5) , 101469
Primary polydipsia: Update
- 1 June 2019
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 288, 1-11
Circuit activity underlying a distinct modulator of prepulse inhibition
- 1 June 2019
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 288, 1-11
Circuit activity underlying a distinct modulator of prepulse inhibition
- 1 June 2016
- Published by Longdom Group in Clinical Schizophrenia & Related Psychoses
- Vol. 10 (2) , 120-122
Rapid Rechallenge with Clozapine Following Pronounced Myocarditis in a Treatment-Resistant Schizophrenia Patient
Clozapine is an atypical antipsychotic which is often effective in patients who fail to respond to other antipsychotics, but its use carries substantial risk. Myocarditis is one of the life-threatening adverse effects, which occurs in about 1% of exposed patients. Rechallenge with clozapine is controversial, particularly shortly after the occurrence of the myocarditis, and when there is clear and convincing evidence of cardiac damage. Aggressive use of clozapine, however, may be critical for the recovery of patients early in the course of their illness. Here we report a successful case of clozapine rechallenge following an initial aggressive dosage titration in an inpatient setting.
- 1 June 2016
- Published by Longdom Group in Clinical Schizophrenia & Related Psychoses
- Vol. 10 (2) , 120-122
Rapid Rechallenge with Clozapine Following Pronounced Myocarditis in a Treatment-Resistant Schizophrenia Patient
Clozapine is an atypical antipsychotic which is often effective in patients who fail to respond to other antipsychotics, but its use carries substantial risk. Myocarditis is one of the life-threatening adverse effects, which occurs in about 1% of exposed patients. Rechallenge with clozapine is controversial, particularly shortly after the occurrence of the myocarditis, and when there is clear and convincing evidence of cardiac damage. Aggressive use of clozapine, however, may be critical for the recovery of patients early in the course of their illness. Here we report a successful case of clozapine rechallenge following an initial aggressive dosage titration in an inpatient setting.
- 1 August 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 157 (1-3) , 204-213
Brain circuit dysfunction in a distinct subset of chronic psychotic patients
- 1 August 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 157 (1-3) , 204-213
Brain circuit dysfunction in a distinct subset of chronic psychotic patients
- 1 July 2014
- Published by Elsevier in Psychiatry Research
- Vol. 217 (3) , 129-133
A systematic review of the ability of urine concentration to distinguish antipsychotic- from psychosis-induced hyponatremia
- 1 July 2014
- Published by Elsevier in Psychiatry Research
- Vol. 217 (3) , 129-133
A systematic review of the ability of urine concentration to distinguish antipsychotic- from psychosis-induced hyponatremia
- 1 April 2014
- Published by Springer Nature
- p. 27-33
Overview of Neurobiology
- 1 April 2014
- Published by Springer Nature
- p. 315-320
Conclusion
- 1 April 2014
- Published by Springer Nature
- p. 3-12
Introduction